Impressing analysts with a big Q3, AstraZeneca whisks away the losers in the pipeline
A little more than 2 years after they started a pivotal Phase III study, AstraZeneca and its partners at Chi-Med have officially iced the late-stage, head-to-head study of savolitinib with Sutent in MET-driven cases of papillary renal cell carcinoma. That was one of 6 pipeline programs that ended in the scrap heap in the Q3 cleanup at the pharma giant.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
